1. Home
  2. STRO vs AIP Comparison

STRO vs AIP Comparison

Compare STRO & AIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STRO
  • AIP
  • Stock Information
  • Founded
  • STRO 2003
  • AIP 2003
  • Country
  • STRO United States
  • AIP United States
  • Employees
  • STRO N/A
  • AIP N/A
  • Industry
  • STRO Biotechnology: Biological Products (No Diagnostic Substances)
  • AIP Semiconductors
  • Sector
  • STRO Health Care
  • AIP Technology
  • Exchange
  • STRO Nasdaq
  • AIP Nasdaq
  • Market Cap
  • STRO 74.3M
  • AIP 391.5M
  • IPO Year
  • STRO 2018
  • AIP 2021
  • Fundamental
  • Price
  • STRO $0.85
  • AIP $9.23
  • Analyst Decision
  • STRO Hold
  • AIP Strong Buy
  • Analyst Count
  • STRO 7
  • AIP 3
  • Target Price
  • STRO $1.97
  • AIP $15.00
  • AVG Volume (30 Days)
  • STRO 520.3K
  • AIP 522.2K
  • Earning Date
  • STRO 11-12-2025
  • AIP 11-04-2025
  • Dividend Yield
  • STRO N/A
  • AIP N/A
  • EPS Growth
  • STRO N/A
  • AIP N/A
  • EPS
  • STRO N/A
  • AIP N/A
  • Revenue
  • STRO $104,473,000.00
  • AIP $63,236,000.00
  • Revenue This Year
  • STRO $65.48
  • AIP $19.40
  • Revenue Next Year
  • STRO N/A
  • AIP $17.91
  • P/E Ratio
  • STRO N/A
  • AIP N/A
  • Revenue Growth
  • STRO N/A
  • AIP 18.64
  • 52 Week Low
  • STRO $0.52
  • AIP $5.46
  • 52 Week High
  • STRO $4.60
  • AIP $14.29
  • Technical
  • Relative Strength Index (RSI)
  • STRO 45.04
  • AIP 50.76
  • Support Level
  • STRO $0.85
  • AIP $8.42
  • Resistance Level
  • STRO $1.01
  • AIP $9.00
  • Average True Range (ATR)
  • STRO 0.09
  • AIP 0.37
  • MACD
  • STRO -0.01
  • AIP 0.02
  • Stochastic Oscillator
  • STRO 5.30
  • AIP 55.10

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About AIP Arteris Inc.

Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum profit from Asia Pacific.

Share on Social Networks: